Decentralised paediatric clinical trials trending up but study execution critical
Paediatric clinical trial recruitment is inherently challenging. There are obstacles to trial participation like school schedules, parents needing to take…
All articles by Andrew Hillman
Andrew Hillman
@ajhillman_ddj
Andrew Hillman is a data journalist at GlobalData Media, specialising in healthcare and pharmaceutical coverage. He is a graduate of Birmingham City University's data journalism program and previously worked as an analyst and modeller in the emergency healthcare sector.
-
-
Beyond clinical trial design: factors that impact decentralisation
When it comes to integrating decentralised elements into a clinical trial, the patient is the centre of the issue. And…
-
Women’s health clinical trials: breaking down barriers through decentralisation
Patient recruitment is one of the most challenging aspects of running clinical trials. Certain socioeconomic factors, such as the disproportionate…
-
The great wall: why overseas sponsors are yet to fully tap into China’s clinical trial resources
Need to know: China is a tempting country to run clinical trials from due to its large pool of treatment-naïve…
-
DCT Adoption Tracker: Top 3 clinical trial decentralisation trends in Q1 2022
In our first update of the Decentralised Clinical Trials (DCT) Adoption Tracker for 2022, we saw three notable trends on…
-
Covid-19 two years on: persistent symptoms of clinical trial disruption trouble certain therapy areas
Need to Know: Using the GlobalData Clinical Trials database, Clinical Trials Arena can reveal the breakdown of disrupted clinical trials…
-
Trial Activity Snapshot: Did Australia’s “zero-Covid” plan protect clinical trial activity?
Need to know: Despite the pandemic, Australia’s new non-Covid-19 interventional drug trial numbers exceeded prepandemic levels by August 2020, with…
-
Filings buzz in pharma: 92% increase in internet of things mentions in Q2
Mentions of the internet of things within the filings of companies in the pharmaceutical industry rose 92% between the first…
-
2022 forecast: diabetes, cardiovascular, respiratory trial activity set to rebound
Need to know: The number of 2022 diabetes clinical trials is on track to surpass this year’s figures. This would…
-
2022 forecast: decentralised trials to reach new heights with 28% jump
Projected 28% Growth for Decentralized Trials in 2022 Need to know: A record number of around 1,300 trials with a…